About the Company
Organovo is an early-stage biotechnology company that is developing and utilizing highly customized 3D human tissues as dynamic models of healthy and diseased human biology for drug development. The company's proprietary technology is being used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Organovo's advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs for selected therapeutic areas.
Employees
6
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ONVO News
Why Organovo Stock Is Up Today
Organovo Holdings, Inc. (NASDAQ:ONVO) shares are trading higher Monday after the company announced Phase 2 results for FXR314 ...
Interview with the Founder and Executive Chairman: Organovo Holdings Inc. (NASDAQ:ONVO)
Just to start things off, could you tell us a bit about what Organovo Holdings does? Mr. Murphy: Absolutely. Organovo is advancing a first-in-class FXR agonist for IBD. FXR agonists haven’t been ...
ONVO Organovo Holdings, Inc.
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen ...
Organovo gets grant for bioprinted renal tissue for assessing renal toxicity of therapeutic agents
Assess renal toxicity with Organovo's patented bioprinted renal tubule model. Measure viability and functionality of renal cells for accurate results.
Organovo Holdings, Inc.
Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary ...
Organovo Holdings, Inc. (ONVO)
SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration ...
Organovo Holdings Inc ONVO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Organovo Holdings Inc ONVO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Organovo Holdings Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Organovo Holdings Inc (ONVO)
Rising rate concerns cast a pall on Wall Street, bolstering the need for value investing. After all, investors love stocks with a low price-to-earnings (P/E) ratio. The perception ...
Loading the latest forecasts...